# An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris

> **NCT01785836** · PHASE1 · WITHDRAWN · sponsor: **Allergan**

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Dapsone Formulation A
- **DRUG:** Dapsone Formulation B
- **DRUG:** Dapsone Formulation C
- **DRUG:** Dapsone 5% Gel

## Key facts

- **NCT ID:** NCT01785836
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-03
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never initiated due to company decision. No study subjects were ever enrolled or dosed.
- **Last updated:** 2013-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01785836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01785836, "An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01785836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*